BioSpace News Archive

Business

Senate Trims Massive Spending Bill, Snipping Out Biden’s Cancer-Ending Agency

Biden’s campaign trail promise to cure cancer is hanging in the balance as his plan for a new biomedical research agency is being axed from the Democrats’ social spending package.

October 11, 2021
·
2 min read
·
Kate Goodwin
Drug Development

Fauci Gives Go-Ahead to Trick-or-Treaters and More COVID-19 News

According to Fauci, kids can safely go trick-or-treating outdoors this Halloween. He did add that children who are eligible for COVID-19 vaccinations should do so for an “extra degree of protection.”

October 11, 2021
·
3 min read
·
Mark Terry
Policy

Protagonist Back in the Saddle with PV Drug as FDA Lifts Hold

Protagonist Therapeutics announced Monday morning that the FDA had removed the hold on PV drug candidate rusfertide, clearing the way for all trials to resume.

October 11, 2021
·
2 min read
·
Heather McKenzie
FDA

FDA Greenlights Enzyvant Drug Rethymic for Ultra-Rare Pediatric Disease

The incidence of congenital athymia is about 17 to 24 lives births each year in the U.S. The therapy is a one-time regenerative tissue-based therapy.

October 11, 2021
·
3 min read
·
Mark Terry
Business

GSK Continues to Switch Up Scenery in Advance of Upcoming Demerger

The scenery will continue to change for GlaxoSmithKline as the company’s planned demerger looms on the horizon. On Monday, GSK gave a glimpse of where the companies will call home post-split.

October 11, 2021
·
2 min read
·
Ellen Camacho
Business

Ensoma Taps Gene Therapy Leader as First CEO

After guiding BlueRock Therapeutics and its potential Parkinson’s disease stem cell therapy into the clinic and to a $1 billion acquisition by Bayer, Emile Nuwaysir is taking on gene therapy startup Ensoma as CEO.

October 11, 2021
·
2 min read
·
Alex Keown
Drug Development

Alzheimer’s Treatment Drug Granted FDA Breakthrough Designation as Space Heats Up

Roche’s candidate drug for Alzheimer’s treatment received breakthrough therapy designation which has increased its chance of getting full FDA approval.

October 11, 2021
·
2 min read
·
Vanessa Doctor, RN
Business

Pacira Adds Flexion’s Zilretta to Non-Opioid Pipeline in $427 Million Deal

Zilretta is the first treatment approved by the U.S. FDA for OA knee pain that uses extended-release microsphere technology.

October 11, 2021
·
2 min read
·
Alex Keown
Drug Development

Idorsia Drug Flops in Fabry Disease, Program’s Future Pending

Its Phase III MODIFY study had hoped to find a positive effect of its oral substrate reduction therapy lucerastat on adult patients who have been diagnosed with Fabry disease.

October 11, 2021
·
2 min read
·
Vanessa Doctor, RN
Deals

Supernus Snags Parkinson’s-focused Adamas Pharmaceuticals in $400 Million Deal

Shares of Adamas Pharmaceuticals are up nearly 75% this morning after Supernus Pharmaceuticals announced it was acquiring the company and its Parkinson’s disease products.

October 11, 2021
·
2 min read
·
Alex Keown